A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Clinical Trial Grant
Awarded By
Janssen Research & Development, LLC
Start Date
November 19, 2025
End Date
December 29, 2025
Awarded By
Janssen Research & Development, LLC
Start Date
November 19, 2025
End Date
December 29, 2025